Medicus Pharma (MDCX) Competitors $3.38 +0.16 (+4.97%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MDCX vs. ACTU, CRBU, NMRA, VXRT, NKTX, IKT, GLSI, FTLF, KRRO, and TARAShould you be buying Medicus Pharma stock or one of its competitors? The main competitors of Medicus Pharma include Actuate Therapeutics (ACTU), Caribou Biosciences (CRBU), Neumora Therapeutics (NMRA), Vaxart (VXRT), Nkarta (NKTX), Inhibikase Therapeutics (IKT), Greenwich LifeSciences (GLSI), FitLife Brands (FTLF), Korro Bio (KRRO), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. Medicus Pharma vs. Its Competitors Actuate Therapeutics Caribou Biosciences Neumora Therapeutics Vaxart Nkarta Inhibikase Therapeutics Greenwich LifeSciences FitLife Brands Korro Bio Protara Therapeutics Actuate Therapeutics (NASDAQ:ACTU) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment. Is ACTU or MDCX more profitable? Actuate Therapeutics' return on equity of 0.00% beat Medicus Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A -339.73% Medicus Pharma N/A -380.03%-224.22% Do analysts rate ACTU or MDCX? Actuate Therapeutics currently has a consensus target price of $20.50, suggesting a potential upside of 214.18%. Medicus Pharma has a consensus target price of $23.50, suggesting a potential upside of 595.27%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Medicus Pharma is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Medicus Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Which has higher earnings and valuation, ACTU or MDCX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$27.28MN/AN/AMedicus PharmaN/AN/A-$11.16M-$1.16-2.91 Does the media refer more to ACTU or MDCX? In the previous week, Actuate Therapeutics had 4 more articles in the media than Medicus Pharma. MarketBeat recorded 8 mentions for Actuate Therapeutics and 4 mentions for Medicus Pharma. Actuate Therapeutics' average media sentiment score of 1.69 beat Medicus Pharma's score of 0.75 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Medicus Pharma 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMedicus Pharma beats Actuate Therapeutics on 5 of the 8 factors compared between the two stocks. Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDCX vs. The Competition Export to ExcelMetricMedicus PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.87M$2.88B$5.50B$9.01BDividend YieldN/A2.43%5.38%4.04%P/E Ratio-2.9121.5627.6020.30Price / SalesN/A172.94369.09103.84Price / CashN/A41.9536.6357.47Price / Book11.667.518.055.68Net Income-$11.16M-$55.05M$3.18B$249.13M7 Day Performance16.55%4.61%2.82%3.30%1 Month Performance22.91%4.89%3.70%5.20%1 Year PerformanceN/A5.84%35.41%21.38% Medicus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDCXMedicus Pharma2.0949 of 5 stars$3.38+5.0%$23.50+595.3%N/A$45.87MN/A-2.91N/AAnalyst ForecastGap UpACTUActuate Therapeutics3.045 of 5 stars$6.44-4.6%$20.50+218.3%N/A$132.43MN/A0.0010Positive NewsCRBUCaribou Biosciences2.3387 of 5 stars$1.42+0.7%$8.50+498.6%-15.0%$131.14M$9.99M-0.88100News CoverageNMRANeumora Therapeutics2.6138 of 5 stars$0.81-0.1%$9.29+1,049.4%-91.7%$130.76MN/A-0.50108Gap UpVXRTVaxart2.3021 of 5 stars$0.54-3.9%$3.00+457.6%-33.1%$127.85M$28.70M-1.99120NKTXNkarta2.2838 of 5 stars$1.78+1.7%$14.33+705.2%-67.2%$124.18MN/A-1.18140IKTInhibikase Therapeutics1.405 of 5 stars$1.67+0.6%$6.50+289.2%+64.3%$124.15M$260K-0.636News CoverageGLSIGreenwich LifeSciences1.5357 of 5 stars$9.00-0.6%$39.00+333.3%-39.9%$120.98MN/A-7.143FTLFFitLife Brands4.0709 of 5 stars$12.81-0.2%$20.50+60.0%-7.3%$120.58M$64.47M15.2520KRROKorro Bio2.3888 of 5 stars$11.94-5.9%$102.43+757.9%-66.3%$119.17M$2.27M-1.2670TARAProtara Therapeutics1.7712 of 5 stars$2.89-5.6%$20.50+609.3%+38.4%$118.06MN/A-1.6830 Related Companies and Tools Related Companies Actuate Therapeutics Alternatives Caribou Biosciences Alternatives Neumora Therapeutics Alternatives Vaxart Alternatives Nkarta Alternatives Inhibikase Therapeutics Alternatives Greenwich LifeSciences Alternatives FitLife Brands Alternatives Korro Bio Alternatives Protara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDCX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
